You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌》石藥(01093.HK)首季純利14.78億人幣跌8.4%
阿思達克 05-29 12:02
石藥集團(01093.HK)公佈截至今年3月底止首季業績,營業額70.15億元人民幣(下同),按年跌21.9%。純利14.78億元,按年跌8.4%;每股盈利12.91分。 撇除按公平值計入損益的金融資產之公平值變動及以股份爲基礎之僱員酬金開支後,股東應佔基本溢利爲14.11億元,較去年同期減少18.2%。 成藥業務於本期實現收入55億元,較去年同期減少27.3%,主要是部份產品的銷售收入受到藥品集中帶量採購及國家醫保藥品目錄內藥品的價格調整等行業政策的持續影響所致。 本期的研發費用較去年同期增加11.4%至13.02億元,約佔成藥業務收入23.7%。目前有近90個產品在臨牀試驗的不同階段,其中10個已遞交上市申請,逾30個重點產品處於註冊臨牀階段。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account